Free Trial Information
BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

...research from his lab, including Hydra Biosciences Inc., Navigen Pharmaceuticals Inc....
Read More
BioCentury | Jun 9, 2016
Distillery Therapeutics

Therapeutics: ADP-ribosylation factor 6 (ARF6); G protein q polypeptide (GNAQ; G-ALPHA-q)

...ARF6 decreased tumor number and growth compared with vehicle or scrambled shRNA. Next steps by Navigen Pharmaceuticals Inc....
...testing and improving safety and efficacy of ARF6 inhibitors in animal models of uveal melanoma. Navigen...
...Yoo, J. et al. Cancer Cell; published online June 2, 2016 doi:10.1016/j.ccell.2016.04.015 CONTACT: Kirill Ostanin, Navigen...
Read More
BioCentury | Apr 15, 2013
Company News

Verinata management update

Verinata Health Inc. , Redwood City, Calif. Business: Diagnostic Hired: Keith Jones as SVP of R&D, formerly VP of assay and application product development at Affymetrix Inc. ; and Vance Vanier as president, formerly president and...
Read More
BioCentury | Jan 21, 2013
Finance

Genetics for docs

Genetics for docs Silicon Valley Biosystems Corp. is developing genomic-based algorithms it says will provide "precise actionable" diagnostic results to clinicians at the bedside. The company, which made its debut last week, has undisclosed funding...
Read More
BioCentury | Jan 21, 2013
Company News

Silicon Valley Biosystems diagnostic news

Diagnostics service company Silicon Valley Biosystems debuted last week with funding from Sequoia Capital. The company had raised an undisclosed amount in a seed and series A round from Sequoia. The company was founded in...
Read More
BioCentury | Oct 15, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Celgene Corp. (NASDAQ:CELG) was up $0.70 to $78.42 on Friday after FDA approved an sNDA for Abraxane nab-paclitaxel for first-line treatment of advanced non-small cell lung cancer (NSCLC). The product was first approved...
Read More
BioCentury | Oct 15, 2012
Company News

Compendia Bioscience, Life Technologies deal

Life Technologies acquired cancer bioinformatics company Compendia. Life Tech said the acquisition is part of its plan to move into cancer diagnostics, which began in July with the acquisitions of Pinpoint Genomics Inc. and Navigenics...
Read More
BioCentury | Oct 9, 2012
Company News

Life Tech acquires bioinformatics firm Compendia

Life Technologies Corp. (NASDAQ:LIFE) acquired cancer bioinformatics company Compendia Bioscience Inc. (Ann Arbor, Mich.). The companies did not disclose financial terms. Life Tech said the acquisition is part of its plan to move into cancer...
Read More
BioCentury | Sep 13, 2012
Cover Story

VEGF reflects on itself

...Kay and colleagues have developed d-peptide HIV entry inhibitors that are exclusively licensed to Navigen Pharmaceuticals Inc....
...Massachusetts Institute of Technology , Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Navigen Pharmaceuticals Inc....
Read More
BioCentury | Jul 23, 2012
Company News

Life Technologies, Navigenics deal

Life Technologies acquired Navigenics for an undisclosed sum. Life Technologies said Navigenics' CLIA-certified laboratory will allow Life Technologies to develop and market laboratory-developed tests, as well as market approved assays. The company also said the...
Read More
Items per page:
1 - 10 of 27
BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

...research from his lab, including Hydra Biosciences Inc., Navigen Pharmaceuticals Inc....
Read More
BioCentury | Jun 9, 2016
Distillery Therapeutics

Therapeutics: ADP-ribosylation factor 6 (ARF6); G protein q polypeptide (GNAQ; G-ALPHA-q)

...ARF6 decreased tumor number and growth compared with vehicle or scrambled shRNA. Next steps by Navigen Pharmaceuticals Inc....
...testing and improving safety and efficacy of ARF6 inhibitors in animal models of uveal melanoma. Navigen...
...Yoo, J. et al. Cancer Cell; published online June 2, 2016 doi:10.1016/j.ccell.2016.04.015 CONTACT: Kirill Ostanin, Navigen...
Read More
BioCentury | Apr 15, 2013
Company News

Verinata management update

Verinata Health Inc. , Redwood City, Calif. Business: Diagnostic Hired: Keith Jones as SVP of R&D, formerly VP of assay and application product development at Affymetrix Inc. ; and Vance Vanier as president, formerly president and...
Read More
BioCentury | Jan 21, 2013
Finance

Genetics for docs

Genetics for docs Silicon Valley Biosystems Corp. is developing genomic-based algorithms it says will provide "precise actionable" diagnostic results to clinicians at the bedside. The company, which made its debut last week, has undisclosed funding...
Read More
BioCentury | Jan 21, 2013
Company News

Silicon Valley Biosystems diagnostic news

Diagnostics service company Silicon Valley Biosystems debuted last week with funding from Sequoia Capital. The company had raised an undisclosed amount in a seed and series A round from Sequoia. The company was founded in...
Read More
BioCentury | Oct 15, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Celgene Corp. (NASDAQ:CELG) was up $0.70 to $78.42 on Friday after FDA approved an sNDA for Abraxane nab-paclitaxel for first-line treatment of advanced non-small cell lung cancer (NSCLC). The product was first approved...
Read More
BioCentury | Oct 15, 2012
Company News

Compendia Bioscience, Life Technologies deal

Life Technologies acquired cancer bioinformatics company Compendia. Life Tech said the acquisition is part of its plan to move into cancer diagnostics, which began in July with the acquisitions of Pinpoint Genomics Inc. and Navigenics...
Read More
BioCentury | Oct 9, 2012
Company News

Life Tech acquires bioinformatics firm Compendia

Life Technologies Corp. (NASDAQ:LIFE) acquired cancer bioinformatics company Compendia Bioscience Inc. (Ann Arbor, Mich.). The companies did not disclose financial terms. Life Tech said the acquisition is part of its plan to move into cancer...
Read More
BioCentury | Sep 13, 2012
Cover Story

VEGF reflects on itself

...Kay and colleagues have developed d-peptide HIV entry inhibitors that are exclusively licensed to Navigen Pharmaceuticals Inc....
...Massachusetts Institute of Technology , Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Navigen Pharmaceuticals Inc....
Read More
BioCentury | Jul 23, 2012
Company News

Life Technologies, Navigenics deal

Life Technologies acquired Navigenics for an undisclosed sum. Life Technologies said Navigenics' CLIA-certified laboratory will allow Life Technologies to develop and market laboratory-developed tests, as well as market approved assays. The company also said the...
Read More
Items per page:
1 - 10 of 27